 |
12.04.2010 Tridelity signs 3D partnership with two leading software companies Award-winning TRIDELITY partners with two of the world's leading imaging software companies to use its 3D "glasses-free" screens for cutting-edge scientific and medical applications. |
|
21.03.2010 Neuroproof ready to enter early alliances with CNS pharma After reaching breakeven 2009 and maturing its unique neuronal-cells-on-chip screening platform, Neuroproof will enter early alliances with big pharma in the CNS market. Own discovery programmes will focus on Alzheimer, depression, anxiety and pain. |
|
16.03.2010 Neuroproof releases leading cell-on-chip CNS drug screening database NeuroProof's database with over 100 characterized substances containing precise electrophysiological action profiles released. NeuroProof is the world leader in the long term cultivation of primary neurone glia co‐cultures on MEA neurochips. |
|
03.03.2010 ARIVIS Software helps to elucidate Alzheimer ARIVIS Browser helps to manage the enormous image data produced by high-resolution slide scans. These are used for the elucidation of neurodegenerative diseases like Alzheimer, e.g. for the 3D quantification of tissue structures. |
|
16.02.2010 Creative Antibiotics' drug prevents chlamydia infection Positive in vivo data show that Creative Antibiotics drug substance can prevent chlamydia infection. The study, which forms part of a larger project relating to sexually transmitted diseases, was performed by researchers at the University of California. |
